Tolcapone: a review of its use in the management of Parkinson's disease |
| |
Authors: | Keating Gillian M Lyseng-Williamson Katherine A |
| |
Affiliation: | Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz |
| |
Abstract: | Tolcapone (Tasmar) is a selective, reversible inhibitor of peripheral and central catechol-O-methyltransferase (COMT). Results of well designed studies indicate that oral tolcapone is an effective adjunct to levodopa plus a peripheral dopa-decarboxylase inhibitor (DDCI) in patients with fluctuating Parkinson's disease. Tolcapone significantly improves levodopa-induced motor fluctuations and significantly reduces levodopa requirements. The drug is generally well tolerated, with the most commonly occurring adverse events being dopaminergic related. Thus, tolcapone is a useful option in patients with fluctuating Parkinson's disease who are receiving levodopa/DDCI and are not responding to, or are not candidates for, other adjunctive treatments. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|